☰

Kyle D. Null, Ph.D. - Publications

Affiliations: 
2012 Pharmacy Administration The University of Mississippi, USA 
Area:
Health Care Management, Pharmacy
Tree Info Similar researchers PubMed Report error

9/40 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any inaccuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2013 Mahabaleshwarkar RK, Yang Y, Datar MV, Bentley JP, Strum MW, Banahan BF, Null KD. Risk of adverse cardiovascular outcomes and all-cause mortality associated with concomitant use of clopidogrel and proton pump inhibitors in elderly patients. Current Medical Research and Opinion. 29: 315-23. PMID 23362935 DOI: 10.1185/03007995.2013.772051  0.58
2013 Null K, Bentley J, West-Strum D, Yang Y. Refining The Risk-Adjusted Capitated Payment Methodologies For Medicare Part C (CMS-HCC) And Part D (CMS-RXHCC) Plans Using The Medication Exposure Measure (MEM) Value in Health. 16: A256-A257. DOI: 10.1016/J.Jval.2013.03.1312  0.537
2012 Mahabaleshwarkar R, Yang Y, Datar M, Bentley JP, Strum M, Banahan BFI, Null KD. PCV6 Risk of Adverse Cardiovascular Outcomes Associated with Concomitant Use of Clopidogrel and Proton Pump Inhibitors in Elderly Medicare Beneficiaries Value in Health. 15. DOI: 10.1016/J.Jval.2012.03.609  0.554
2011 Khanna R, Dharmarajan S, Null K, Bentley J, Pace P, Banahan B. PIH34 IMPLEMENTATION OF A STATE MEDICAID PRESCRIPTION CAP POLICY: IS THERE AN IMPACT ON BENEFICIARIES' MEDICAL SERVICES UTILIZATION AND COSTS? Value in Health. 14: A111. DOI: 10.1016/J.Jval.2011.02.618  0.525
2011 Lokhandwala T, Yang Y, Thumula V, Bentley J, Strum M, Banahan B, Null K. PCV17 PREDICTORS OF TIME TO DISCONTINUE BETA-BLOCKER FOLLOWING ACUTE MYOCARDIAL INFARCTION: AN ANALYSIS OF THE MEDICARE 5% NATIONAL SAMPLE DATA 2006-2007 Value in Health. 14: A35. DOI: 10.1016/J.Jval.2011.02.205  0.663
2011 Dharmarajan S, Yang Y, Athavale A, Bentley J, Null K, Banahan B. PCV3 RISK OF HOSPITALIZATIONS FOR VENOUS THROMBOEMBOLISM IN ATYPICAL VERSUS TYPICAL ANTIPSYCHOTIC USERS IN A NATIONAL SAMPLE OF MEDICARE BENEFICIARIES: A CLAIMS DATA ANALYSIS Value in Health. 14: A32-A33. DOI: 10.1016/J.Jval.2011.02.192  0.584
2011 Dharmarajan S, Yang Y, Athavale A, Bentley J, Null K, Banahan B. PMH3 RISK OF HIP FRACTURES IN ELDERLY MEDICARE BENEFICIARIES USING ATYPICAL OR TYPICAL ANTIPSYCHOTICS: A PROPENSITY SCORE ANALYSIS Value in Health. 14: A185-A186. DOI: 10.1016/J.Jval.2011.02.1027  0.535
2011 Dharmarajan S, Yang Y, Athavale A, Bentley J, Null K, Banahan B. PMH2 RISK OF HOSPITALIZATION FOR PNEUMONIA ASSOCIATED WITH THE USE OF ATYPICAL VERSUS TYPICAL ANTIPSYCHOTICS IN A NATIONAL SAMPLE OF MEDICARE BENEFICIARIES Value in Health. 14: A185. DOI: 10.1016/J.Jval.2011.02.1026  0.589
2011 Lokhandwala T, Yang Y, Thumula V, Bentley J, Strum M, Banahan B, Null K. MC4 LONG TERM PERSISTENCE WITH ACEI/ARB THERAPY AFTER ACUTE MYOCARDIAL INFARCTION: AN ANALYSIS OF THE 2006-2007 MEDICARE 5% NATIONAL SAMPLE DATA Value in Health. 14: A9. DOI: 10.1016/J.Jval.2011.02.053  0.666
Low-probability matches (unlikely to be authored by this person)
2020 Moran K, Null K, Huang Z, Lissoos T, Kane S. Response to "Comment on Retrospective Claims Analysis Indirectly Comparing Medication Adherence and Persistence Between Intravenous Biologics and Oral Small-Molecule Therapies in Inflammatory Bowel Diseases". Advances in Therapy. PMID 32173794 DOI: 10.1007/S12325-020-01274-5  0.296
2019 Patel H, Latremouille-Viau D, Serre D, Lissoos T, Null KD, Owen G, Campbell-Hill S. 849 Risk of Reoccurrence of Perianal Fistulas in Patients With Crohn’s Disease in the United States: A Retrospective Claims Database Study American Journal of Gastroenterology. 114: S490-S491. DOI: 10.14309/01.Ajg.0000592932.56386.Cf  0.295
2019 Moran K, Null K, Huang Z, Lissoos T, Kane S. Retrospective Claims Analysis Indirectly Comparing Medication Adherence and Persistence Between Intravenous Biologics and Oral Small-Molecule Therapies in Inflammatory Bowel Diseases. Advances in Therapy. PMID 31385283 DOI: 10.1007/S12325-019-01037-X  0.285
2018 Kane S, Moran K, Null K, Huang Z, Lissoos T. P561 A comparison of medication adherence and persistence between intravenous biologics and oral small-molecule therapies Journal of Crohns & Colitis. 12. DOI: 10.1093/Ecco-Jcc/Jjx180.688  0.281
2018 Kane SV, Moran K, Null KD, Huang Z, Lissoos T. Su1008 - A Comparison of Medication Adherence and Persistence Between Intrevenous Biologics and Oral Small-Molecule Therapies Gastroenterology. 154. DOI: 10.1016/S0016-5085(18)31766-9  0.28
2018 Null KD, Chang HL, Lissoos T, Luo M, Cohen B, Sands BE, Atreja A. Su1019 - Adherence and Persistence with Vedolizumab Among Patients with Inflammatory Bowel Disease in an Academic Medical Center Gastroenterology. 154. DOI: 10.1016/S0016-5085(18)31777-3  0.278
2018 Null K, Chang HL, Lissoos T, Luo M, Cohen B, Sands BE, Atreja A. P525 Adherence and persistence with vedolizumab among patients with inflammatory bowel disease in an academic medical centre Journal of Crohns & Colitis. 12. DOI: 10.1093/Ecco-Jcc/Jjx180.652  0.276
2016 Demuth D, Patel H, Chastek B, Lee B, Khalid JM, Null KD. Real-World Treatment Persistence with Vedolizumab in Crohnʼs Disease and Ulcerative Colitis Patients in the United States (US): A Retrospective Analysis Using the Optum Research Database American Journal of Gastroenterology. 111: S324. DOI: 10.14309/00000434-201610001-00721  0.272
2015 Null KD, Moll K, Cappelleri JC, Sadosky A, Parsons B, Pasquale MK. Trends associated with Implementing and Lifting a step Therapy Policy for pregabalin in the humana Medicare Population: an Interrupted time series analysis Value in Health. 18. DOI: 10.1016/J.Jval.2015.03.1688  0.269
2016 Null KD, Visaria J, Demuth D, Patel H, Zhou S, Lissoos T, Luo M. Real-World Treatment Persistence with Vedolizumab in Patients with Ulcerative Colitis and Crohnʼs Disease: A Retrospective Claims Analysis in the U.S. American Journal of Gastroenterology. 111: S322-S324. DOI: 10.14309/00000434-201610001-00718  0.266
2017 Patel H, Chastek B, Null KD, Demuth D. Discontinuation of Corticosteroids among Crohn's Disease Patients Treated with Vedolizumab in the United States (US) Gastroenterology. 152: S397. DOI: 10.1016/S0016-5085(17)31566-4  0.265
2017 Patel H, Chastek B, Null KD, Demuth D. P531 Discontinuation of corticosteroids among Crohn's disease patients treated with vedolizumab in the United States. Journal of Crohn's & Colitis. 11: S350. PMID 28172674 DOI: 10.1093/Ecco-Jcc/Jjx002.655  0.264
2017 Patel H, Chastek B, Null KD, Demuth D. Discontinuation of Corticosteroids among Ulcerative Colitis Patients Treated with Vedolizumab in the United States (US) Gastroenterology. 152: S396-S397. DOI: 10.1016/S0016-5085(17)31565-2  0.262
2017 Patel H, Chastek B, Null KD, Demuth D. P330 Discontinuation of corticosteroids among ulcerative colitis patients treated with vedolizumab in the United States. Journal of Crohn's & Colitis. 11: S245-S246. PMID 28172865 DOI: 10.1093/Ecco-Jcc/Jjx002.455  0.258
2018 Null K, Kumar V, Lissoos T, Luo M. Infusion administration billing for vedolizumab and infliximab in inflammatory bowel disease. Journal of Medical Economics. 21: 1102-1109. PMID 30101633 DOI: 10.1080/13696998.2018.1511568  0.256
2016 Brown JD, Sheer RL, Null KD, Pasquale MK, Sato R. TEMPORARY REMOVAL: Relative Burden of Community-Acquired Pneumonia Hospitalizations in Seniors. American Journal of Preventive Medicine. PMID 27422702 DOI: 10.1016/J.Amepre.2016.05.015  0.245
2012 Datar M, Banahan BF, Null KD, Hardwick SP, Clark JP. PRS39 Palavizumab (Synagis) Use and Outcomes Among Medicaid Beneficiaries Value in Health. 15. DOI: 10.1016/J.Jval.2012.03.323  0.245
2017 Sheer R, Null KD, Szymanski KA, Sudharshan L, Banovic J, Pasquale MK. Predictors of reaching a serum uric acid goal in patients with gout and treated with febuxostat. Clinicoeconomics and Outcomes Research : Ceor. 9: 629-639. PMID 29066924 DOI: 10.2147/Ceor.S139939  0.241
2017 Kassim O, Micic D, Christensen B, Lissoos T, Luo M, Null KD, Cohen R. Vedolizumab Decreases Utilization of Healthcare Resources in Biologic-naïve Inflammatory Bowel Disease (IBD) Patients: 615 The American Journal of Gastroenterology. 112. DOI: 10.14309/00000434-201710001-00615  0.239
2018 Bain A, Barhoum D, Binaso K, Carson R, Coleman A, Conyers D, Curry D, Davidoff B, Davidson MV, Daw J, Dicesare J, Donelson S, Duhig A, Ginsberg S, Goldstein D, ... ... Null K, et al. AMCP partnership forum: Improving quality, value, and outcomes with patient-reported outcomes Journal of Managed Care Pharmacy. 24: 304-310. PMID 29460679 DOI: 10.18553/Jmcp.2018.17491  0.237
2017 Null KD, Xu Y, Pasquale MK, Su C, Marren A, Harnett J, Mardekian J, Manuchehri A, Healey P. Ulcerative Colitis Treatment Patterns and Cost of Care. Value in Health : the Journal of the International Society For Pharmacoeconomics and Outcomes Research. 20: 752-761. PMID 28577692 DOI: 10.1016/J.Jval.2017.02.005  0.232
2014 Datar M, Null KD, Banahan BF. Evaluation Of Pharmacy Quality Alliance (Pqa) Measures Among Medicaid Beneficiaries With Persistant Asthma Value in Health. 17. DOI: 10.1016/J.Jval.2014.03.1004  0.206
2013 Datar M, Null KD, Hardwick SP, Clark JP. Evaluation Of Asthma-Related Pharmacy Quality Alliance (Pqa) Measures In The Mississippi Medicaid Population Value in Health. 16. DOI: 10.1016/J.Jval.2013.03.1221  0.204
2016 Null KD, Cameron A, Kumar VM, Lissoos T, Luo M. Assessing Administration and Billing of Vedolizumab and Infliximab Across IBD Sites of Care: 720 The American Journal of Gastroenterology. 111. DOI: 10.14309/00000434-201610001-00720  0.193
2013 Ramachandran S, Yang Y, Hardwick S, Clark J, Null K, Banahan B. Patterns of use of atypical antipsychotics in children and young adults Value in Health. 16. DOI: 10.1016/J.Jval.2013.03.1611  0.19
2012 Przybyla SM, Banahan BFI, Null KD, Hardwick SP, Clark JP. PIN63 HIV Treatment Guideline Compliance Among Treatment-NaÏve Mississippi Medicaid Adult Beneficiaries Value in Health. 15. DOI: 10.1016/J.Jval.2012.03.1338  0.189
2014 Shahpurwala Z, Null KD, Clark JP. Multi-Opioid, Multi-Provider Use In Persons Without Cancer Value in Health. 17. DOI: 10.1016/J.Jval.2014.03.881  0.189
2014 Shah R, Mahabaleshwarkar R, Null KD, Hardwick SP, Clark JP. Utilization Of Smoking Cessation Products In The Mississippi Medicaid Fee-For-Service Population Value in Health. 17. DOI: 10.1016/J.Jval.2014.03.1050  0.187
2015 Durkin M, Moll K, Pasquale M, Amos T, Null K. Assessing the impact of varying threshold criteria for Opioid Overutilization Value in Health. 18: A306-A307. DOI: 10.1016/J.Jval.2015.03.1783  0.186
2020 Chen G, Lissoos T, Dieyi C, Null KD. Development and Validation of an Inflammatory Bowel Disease Severity Index Using US Administrative Claims Data: A Retrospective Cohort Study. Inflammatory Bowel Diseases. PMID 33043982 DOI: 10.1093/ibd/izaa263  0.096
2021 Chen G, Pedarla V, Null KD, Cazzetta SE, Khan QR, Schwartz DA. Health Care Costs and Resource Utilization Among Patients With Crohn's Disease With and Without Perianal Fistula. Inflammatory Bowel Diseases. PMID 34525184 DOI: 10.1093/ibd/izab198  0.091
Hide low-probability matches.